3 results
to investigate the safety and efficacy of idarucizumab in reversing the anticoagulation effect of dabigatran, in patients who have uncontrolled bleeding or require emergency surgery or invasive procedures.
Primary: efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active ulcerative colitis. Secondary: safety and tolerability, time course of the efficacy of GSK1605786 continued for up to 16 weeks, anti-…
Primary Objective: To determine the (cost)effectiveness of 5-fluorouracil cream (5FU) and photodynamic therapy (PDT), compared to surgical excision (SE) in Bowen*s Disease (BD).Secondary Objectives: To determine the (cost)effectiveness of 5-…